Comparison · NCT02736175-sae
OTX-DP vs Placebo Vehicle: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. OTX-DP vs Placebo Vehicle: serious adverse events. Trial comparisons, record NCT02736175-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02736175-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0139 | 0.00473 | 0.04 | wilson | |
| Risk in group 2 | 0.00905 | 0.00249 | 0.0324 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00484 | -0.0202 | 0.0318 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.53 | 0.259 | 9.09 | log | |
| Odds ratio, group 1 over group 2 | 1.54 | 0.255 | 9.32 | log | |
| Number needed to harm, for one more participant with a serious adverse event on OTX-DP than on Placebo Vehicle | 207 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | OTX-DP | OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use | 3 | 216 | EG000 |
| Group 2 | Placebo Vehicle | PV (placebo drug delivery vehicle) | 2 | 221 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- OTX-15:003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery
- NCT number
- NCT02736175
- Phases
- PHASE3
- Conditions
- Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation
- Interventions
- Dexamethasone, Placebo Vehicle
- Lead sponsor
- Ocular Therapeutix, Inc.
- Results first posted
- 2017-10-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02736175?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02736175-sae